The latest update is out from BioArctic AB Class B ( ($SE:BIOA.B) ).
BioArctic AB has expanded its Phase 2a EXIST study to include Multiple System Atrophy (MSA) patients, following regulatory approval in Spain and Poland. This expansion marks a significant step in developing exidavnemab, a monoclonal antibody targeting alpha-synuclein aggregates, as a potential treatment for MSA and Parkinson’s, addressing a high unmet medical need in neurodegenerative diseases.
More about BioArctic AB Class B
BioArctic AB is a Swedish research-based biopharma company focusing on innovative treatments for neurodegenerative diseases. Known for developing Leqembi®, the first drug to slow Alzheimer’s progression, the company also works on treatments for Parkinson’s, ALS, and enzyme deficiency diseases, utilizing its proprietary BrainTransporter™ technology.
Average Trading Volume: 298,853
Current Market Cap: SEK16.64B
For a thorough assessment of BIOA.B stock, go to TipRanks’ Stock Analysis page.